Sampi K, Masaoka T, Takagi T, Sakamoto S, Mikuni C, Kano Y
Saitama Cancer Center.
Gan To Kagaku Ryoho. 1989 Jan;16(1):79-82.
Patients with lymphoma who became refractory or resistant to standard chemotherapy including anthracyclines were treated with aclarubicin-combined chemotherapy including VP-16, ifosfamide, and carboquone in a multicenter study. Twenty-one patients were entered in this study, and 18 of them were evaluable. The median age was 52 years old (range 27-74), and there were 17 male and 3 female patients. The vast majority of patients were diagnosed as having diffuse lymphoma, of which 10 cases had large cell type. Surface markers were measured in 8 patients, of whom 4 had T-cell lymphoma. Remission was attained in 3 of 18 patients (17%) with one complete and lasting remission with T-cell lymphoma. In conclusion, the response rate in this study was poor, but this type of combination chemotherapy might be considered in patients with T-cell lymphoma.
在一项多中心研究中，对包括蒽环类药物在内的标准化疗难治或耐药的淋巴瘤患者，采用了包括依托泊苷、异环磷酰胺和卡波醌的阿柔比星联合化疗进行治疗。21例患者进入本研究，其中18例可评估。中位年龄为52岁（范围27 - 74岁），男性17例，女性3例。绝大多数患者被诊断为弥漫性淋巴瘤，其中10例为大细胞型。对8例患者进行了表面标志物检测，其中4例为T细胞淋巴瘤。18例患者中有3例（17%）获得缓解，其中1例T细胞淋巴瘤患者实现了完全且持久的缓解。总之，本研究中的缓解率较低，但对于T细胞淋巴瘤患者可考虑使用这种联合化疗方案。
